Amgen director awarded 665 RSUs in stock grant

Druker Brian reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Druker Brian reported acquisition or exercise transactions in this Form 4 filing.

Amgen Inc. director Brian Druker received an equity award of 665 shares of Amgen common stock as a grant under the company’s director incentive program. The award was in the form of Restricted Stock Units (RSUs) that vested immediately and are paid in common shares on a one-to-one basis.

Following this grant, Druker directly holds 8,391 shares of Amgen common stock, which include 408 dividend equivalents (DEs) credited to his unvested RSUs under a qualifying dividend reinvestment plan.

Insights

Equity Compensation Analyst

Routine director RSU grant; small, compensation-related equity increase.

Director Brian Druker received 665 Restricted Stock Units of Amgen Inc. common stock as a grant under the company’s 2009 director incentive framework. The RSUs vested immediately and are settled in common shares on a one-to-one basis, so this is compensation, not an open-market purchase.

The filing notes 8,391 shares held directly after the grant, including 408 dividend equivalents credited to unvested RSUs through a dividend reinvestment feature. With no open-market buying or selling, this event is generally viewed as routine board compensation rather than a directional bet on the stock.

Insider Trade Summary

Grant/Award: 665 shares

Grant/Award 1 txn

Insider Druker Brian

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	665	$0.00	$0.00

Holdings After Transaction: Common Stock — 8,391 shares (Direct)

Footnotes (2)

1. F1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.
2. F2. These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

RSU grant size: 665 shares Shares after transaction: 8,391 shares Dividend equivalents: 408 DEs +1 more

4 metrics

RSU grant size 665 shares Restricted Stock Units granted to director on 2026-05-19

Shares after transaction 8,391 shares Total common stock directly held following grant

Dividend equivalents 408 DEs Dividend equivalents credited to unvested RSUs under reinvestment plan

Grant price $0.00 per share RSUs granted as compensation, not purchased in market

Key Terms

Restricted Stock Units (RSUs), dividend equivalents (DEs), dividend reinvestment plan, Equity Incentive Plan, +1 more

5 terms

Restricted Stock Units (RSUs) financial

"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program..."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

dividend equivalents (DEs) financial

"These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan..."

dividend reinvestment plan financial

"408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan."

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Equity Incentive Plan financial

"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan..."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

director incentive program financial

"granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen (AMGN) director Brian Druker report in this Form 4?

Brian Druker reported receiving 665 shares of Amgen common stock through a grant of Restricted Stock Units that vested immediately. These RSUs were issued under Amgen’s 2009 director incentive framework and increased his direct holdings to 8,391 shares after the transaction.

Was Brian Druker’s Amgen (AMGN) transaction a market purchase or sale?

The transaction was not a market purchase or sale. It was a grant of 665 Restricted Stock Units, reported with transaction code A for award or other acquisition, that vested immediately and were settled in shares of Amgen common stock as director compensation.

How many Amgen (AMGN) shares does Brian Druker hold after this grant?

After the grant, Brian Druker directly holds 8,391 shares of Amgen common stock. This total includes 408 dividend equivalents credited to his unvested Restricted Stock Units under a qualifying dividend reinvestment plan associated with Amgen’s equity incentive program.

What are the key terms of the RSUs granted to Brian Druker at Amgen (AMGN)?

The Restricted Stock Units were granted under Amgen’s 2009 Director Incentive Program, vested immediately, and are paid in common stock on a one-to-one basis. Vested RSUs may be deferred by the director, with payment following the elected deferral schedule in shares and related cash for fractions.

What are dividend equivalents (DEs) mentioned in Brian Druker’s Amgen (AMGN) filing?

Dividend equivalents are credits tied to unvested RSUs reflecting dividends on Amgen stock. Druker’s holdings include 408 DEs, which are paid out as shares of Amgen common stock on a one-to-one basis according to the original RSU vesting schedule, plus cash for any remaining fractional share amount.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 06:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Druker Brian

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320-1799

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		665	A	$0	8,391(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

2. These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Brian J. Druker	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)